vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and SOUTH PLAINS FINANCIAL, INC. (SPFI). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $54.1M, roughly 1.6× SOUTH PLAINS FINANCIAL, INC.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Ally Financial Inc. is an American bank holding company incorporated in Delaware and headquartered at Ally Detroit Center in Detroit, Michigan. The company provides financial services including car finance, online banking via a direct bank, corporate lending, vehicle insurance, mortgage loans, and other related financing services such as installment sale and lease agreements.
IOVA vs SPFI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $54.1M |
| Net Profit | — | $14.5M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | 26.9% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | — | 18.3% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $54.1M | ||
| Q4 25 | $86.8M | $53.9M | ||
| Q3 25 | $67.5M | $54.2M | ||
| Q2 25 | $60.0M | $54.7M | ||
| Q1 25 | $49.3M | $49.2M | ||
| Q4 24 | $73.7M | $51.9M | ||
| Q3 24 | $58.6M | $47.9M | ||
| Q2 24 | $31.1M | $48.6M |
| Q1 26 | — | $14.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $16.3M | ||
| Q2 25 | $-111.7M | $14.6M | ||
| Q1 25 | $-116.2M | $12.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $11.2M | ||
| Q2 24 | $-97.1M | $11.1M |
| Q1 26 | — | — | ||
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -84.7% | 35.4% | ||
| Q3 25 | -140.7% | 38.1% | ||
| Q2 25 | -189.8% | 34.1% | ||
| Q1 25 | -245.8% | 31.9% | ||
| Q4 24 | -117.5% | 39.9% | ||
| Q3 24 | -152.1% | 29.8% | ||
| Q2 24 | -327.6% | 29.3% |
| Q1 26 | — | 26.9% | ||
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 30.1% | ||
| Q2 25 | -186.2% | 26.7% | ||
| Q1 25 | -235.5% | 25.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 23.4% | ||
| Q2 24 | -312.2% | 22.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.90 | ||
| Q3 25 | — | $0.96 | ||
| Q2 25 | $-0.33 | $0.86 | ||
| Q1 25 | $-0.36 | $0.72 | ||
| Q4 24 | $-0.24 | $0.96 | ||
| Q3 24 | $-0.28 | $0.66 | ||
| Q2 24 | $-0.34 | $0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $722.0M |
| Total DebtLower is stronger | — | $3.0K |
| Stockholders' EquityBook value | $698.6M | $504.9M |
| Total Assets | $913.2M | $4.6B |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $722.0M | ||
| Q4 25 | $297.0M | $552.4M | ||
| Q3 25 | $300.8M | $635.0M | ||
| Q2 25 | $301.2M | $470.5M | ||
| Q1 25 | $359.7M | $536.3M | ||
| Q4 24 | $323.8M | $359.1M | ||
| Q3 24 | $397.5M | $471.2M | ||
| Q2 24 | $412.5M | $298.0M |
| Q1 26 | — | $3.0K | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $504.9M | ||
| Q4 25 | $698.6M | $493.8M | ||
| Q3 25 | $702.3M | $477.8M | ||
| Q2 25 | $698.5M | $454.1M | ||
| Q1 25 | $767.9M | $443.7M | ||
| Q4 24 | $710.4M | $438.9M | ||
| Q3 24 | $773.5M | $443.1M | ||
| Q2 24 | $768.5M | $418.0M |
| Q1 26 | — | $4.6B | ||
| Q4 25 | $913.2M | $4.5B | ||
| Q3 25 | $904.9M | $4.5B | ||
| Q2 25 | $907.4M | $4.4B | ||
| Q1 25 | $966.7M | $4.4B | ||
| Q4 24 | $910.4M | $4.2B | ||
| Q3 24 | $991.1M | $4.3B | ||
| Q2 24 | $964.3M | $4.2B |
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $77.5M | ||
| Q3 25 | $-78.7M | $24.2M | ||
| Q2 25 | $-67.4M | $14.7M | ||
| Q1 25 | $-103.7M | $26.1M | ||
| Q4 24 | $-73.3M | $59.4M | ||
| Q3 24 | $-59.0M | $17.9M | ||
| Q2 24 | $-98.4M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $71.8M | ||
| Q3 25 | $-89.5M | $22.5M | ||
| Q2 25 | $-74.9M | $13.0M | ||
| Q1 25 | $-109.9M | $25.0M | ||
| Q4 24 | $-77.5M | $56.0M | ||
| Q3 24 | $-61.3M | $17.1M | ||
| Q2 24 | $-98.9M | $17.1M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 133.3% | ||
| Q3 25 | -132.7% | 41.5% | ||
| Q2 25 | -124.9% | 23.8% | ||
| Q1 25 | -222.8% | 50.8% | ||
| Q4 24 | -105.1% | 108.0% | ||
| Q3 24 | -104.6% | 35.7% | ||
| Q2 24 | -317.9% | 35.2% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 10.5% | ||
| Q3 25 | 16.1% | 3.2% | ||
| Q2 25 | 12.4% | 3.2% | ||
| Q1 25 | 12.6% | 2.3% | ||
| Q4 24 | 5.7% | 6.5% | ||
| Q3 24 | 3.9% | 1.6% | ||
| Q2 24 | 1.4% | 2.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.12× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.59× | ||
| Q2 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
SPFI
| Net Interest Income | $42.9M | 79% |
| Noninterest Income | $11.3M | 21% |
